Stablix Therapeutics has launched with $63m in equity financing to commercialise research pioneered in Henry Colecraft’s laboratory at Columbia University.
Stablix Therapeutics, a US-based biotechnology company advancing research from Columbia University, launched yesterday with $63m in series A funding led by Versant Ventures.
The round also included Alexandria Venture Investments, the investment arm of life science real estate investment trust Alexandria Real Estate Equities, as well as New Enterprise Associates (NEA), Cormorant Capital and Euclidean Capital.
Stablix has developed targeted protein stabilisation technology that has applications in the treatment of rare diseases, cancer and immunological disorders.
The…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
